Literature DB >> 17921794

Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.

Maria Justiniano1, Sylvia Dold, Luis R Espinoza.   

Abstract

We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis. Profound muscle weakness of lower extremities with inability to stand up and/or walk was present. Elevated muscle enzymes and findings on electromyography were consistent with myopathy. Rapid improvement in muscle strength accompanied by prompt resolution of abnormal elevation of muscle enzymes followed cessation of both medications. Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy. The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness. Four patients with similar clinical and laboratory characteristics to our patient's after the combined use of colchicine and statins have been described in the literature. Patients receiving combination therapy with colchicine and simvastatin, particularly in the presence of renal insufficiency, should be monitored for the development of myopathy, including rhabdomyolysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17921794     DOI: 10.1097/RHU.0b013e318156d977

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  13 in total

Review 1.  Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?

Authors:  Thomas F Whayne
Journal:  Am J Cardiovasc Drugs       Date:  2021-01       Impact factor: 3.571

2.  Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions.

Authors:  Matthew W Davis; Suman Wason
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

Review 3.  Update on colchicine, 2017.

Authors:  Anastasia Slobodnick; Binita Shah; Svetlana Krasnokutsky; Michael H Pillinger
Journal:  Rheumatology (Oxford)       Date:  2018-01-01       Impact factor: 7.580

Review 4.  A "crush" course on rhabdomyolysis: risk stratification and clinical management update for the perioperative clinician.

Authors:  Devan R Cote; Eva Fuentes; Ali H Elsayes; Jonathan J Ross; Sadeq A Quraishi
Journal:  J Anesth       Date:  2020-05-18       Impact factor: 2.078

Review 5.  Colchicine: old and new.

Authors:  Anastasia Slobodnick; Binita Shah; Michael H Pillinger; Svetlana Krasnokutsky
Journal:  Am J Med       Date:  2014-12-30       Impact factor: 4.965

Review 6.  Vascular comorbidities in familial Mediterranean fever.

Authors:  Z Birsin Ozçakar; Fatoş Yalçınkaya
Journal:  Rheumatol Int       Date:  2011-03-25       Impact factor: 2.631

7.  Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database.

Authors:  Pornwalai Boonmuang; Surakit Nathisuwan; Nathorn Chaiyakunapruk; Wimon Suwankesawong; Pattreya Pokhagul; Nattawat Teerawattanapong; Pairin Supsongserm
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

Review 8.  Behcet's Syndrome.

Authors:  Sam R Dalvi; Resit Yildirim; Yusuf Yazici
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

Review 9.  Colchicine-clarithromycin-induced rhabdomyolysis in Familial Mediterranean Fever patients under treatment for Helicobacter pylori.

Authors:  Oren Cohen; Garrett Locketz; Alon Y Hershko; Alexander Gorshtein; Yair Levy
Journal:  Rheumatol Int       Date:  2015-07-26       Impact factor: 2.631

10.  Rosuvastatin and Colchicine combined myotoxicity: lessons to be learnt.

Authors:  Nikolaos Sabanis; Eleni Paschou; Aikaterini Drylli; Panagiota Papanikolaou; Georgios Zagkotsis
Journal:  CEN Case Rep       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.